Episodes
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Published 04/24/23
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Published 04/12/23
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Published 03/28/23
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
Published 03/14/23
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
Published 02/28/23
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
Published 02/14/23
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Published 02/01/23
Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
Published 01/20/23
DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
Published 01/03/23
Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
Published 12/19/22
Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.
Published 11/08/22
Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.
Published 10/27/22
Aetna Wun Trombley, CEO of Lycia Therapeutics, on extracellular protein degraders.
Published 10/11/22
Samantha Truex, CEO of Upstream Bio, on a new approach to treating severe asthma and other inflammatory diseases.
Published 09/26/22
Tim Lu, CEO of Senti Biosciences, on developing gene circuits for cell therapy.
Published 09/07/22
Jo Viney, CEO of Seismic Therapeutic, on discovering new treatments for autoimmune disease.
Published 08/22/22
Ivan Liachko, CEO of Seattle-based Phase Genomics, on assembling accurate genomes and interactomes. He also discusses immigrating from Ukraine as a child, and what brought him and his family to the US.
Published 08/08/22
Dr. Sanduk Ruit of the Tilganga Institute in Kathmandu on restoring eyesight with affordable cataract surgery for the developing world.
Published 07/11/22
Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, on precision neuroscience drug development.
Published 06/22/22
Rahul Singhvi, CEO of Resilience, on rethinking the model for manufacturing of advanced biologics, gene and cell therapies.
Published 06/07/22
Chris Gibson, co-founder and CEO of Recursion, on using new tools to industrialize drug discovery.
Published 05/23/22
Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations.
Published 05/09/22
Bernat Olle, CEO of Vedanta Biosciences, on developing microbiome therapeutics.
Published 04/18/22
Ray Stevens, CEO of ShouTi, on structural biology driven drug discovery.
Published 03/14/22
Michele Andrasik, a clinical health psychologist at the Fred Hutchinson Cancer Research Center, on improving community outreach and diversity in clinical trials.
Published 03/01/22
Listen now
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
